Although IFNα was investigated as a therapeutic molecule in early myeloma treatment trials [41], it was shown that co-cultures with IFNα-producing plasmacytoid DCs demonstrated higher plasma and MM cell proliferation [42,43]. Here, IFNA1 is linked to plasma cell myeloma.